The Latest Breaking News from gene editing

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA)

The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA editing. Its aim is to treat an eye disease called wet age-related macular degeneration that causes vision loss in millions of older people worldwide.

Advocates urge government to allow ‘precision breeding’ to combat disease, but RSPCA warns of ethical dangers

A new study from Stanford Medicine shows how a gene editing tool identified a gene to knock out that could promote activation of neural stem cells.

A geneticist recently discovered the gene that accounts for prickliness across a variety of plants, including roses.

As any avid gardener will tell you, plants with sharp thorns and prickles can leave you looking like you’ve had a run-in with an angry cat. Wouldn’t it be nice to rid plants of their prickles entirely but keep the tasty fruits and beautiful flowers?

The societal implications of this technology are still vast. And researchers can already start exploring the ethics by engaging communities well ahead of time.

Why ethical discussions with the target communities should happen sooner rather than later

With their primary goal to advance scientific knowledge, most scientists are not trained or incentivized to think through the societal implications of the technologies they are developing. Even in genomic medicine, which is geared toward benefiting future patients, time and funding pressures make real-time ethics oversight difficult.